Print this page
-
Biomarkers of Oral Carcinogenesis and Oral Cancer Pain
Protocol: 032202Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy.
Protocol: 032310Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing.
Protocol: 032402Principal Investigator:
- Taha Mur
Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers
Protocol: 192104Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Breast
Cervix
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital
Stomach -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Anus
Cervix
Larynx
Lip, Oral Cavity and Pharynx
Other Female Genital
Other Male Genital